Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00121069
NCT00121069
Completed
Phase 2

Placebo-Controlled Pilot Study of Escitalopram in the Treatment of Specific Phobia

Connor, Kathryn M., M.D.1 site in 1 country12 target enrollmentSeptember 2002
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsPhobic Disorders
DrugsEscitalopram

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Phobic Disorders
Sponsor
Connor, Kathryn M., M.D.
Enrollment
12
Locations
1
Primary Endpoint
Response based on a criterion of 50% or greater reduction in the Marks Main Phobia Questionnaire and Marks Fear Questionnaire from baseline
Status
Completed
Last Updated
20 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

This pilot study is designed to assess the efficacy of escitalopram in the treatment of specific phobia in adult outpatients.

Detailed Description

This double-blind placebo-controlled pilot trial study is designed to assess the efficacy of 12 weeks of escitalopram vs. placebo in the treatment of specific phobia in adult outpatients. It is hypothesized that escitalopram is safe and effective in the treatment of specific phobia.

Registry
clinicaltrials.gov
Start Date
September 2002
End Date
September 2004
Last Updated
20 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Connor, Kathryn M., M.D.

Eligibility Criteria

Inclusion Criteria

  • •Adults 18-65 years of age
  • •DSM-IV criteria for specific phobia according to the MINI
  • •For women of childbearing potential, a negative serum pregnancy test at screening
  • •Written informed consent

Exclusion Criteria

  • •Any current primary DSM-IV diagnosis other than specific phobia
  • •History of DSM-IV substance abuse or dependence within the last months
  • •Lifetime history of bipolar I disorder, schizophrenia or other psychotic disorder, mental retardation, or other pervasive developmental disorder or cognitive disorder due to a general medical condition
  • •Suicide risk or serious suicide attempt within the last year
  • •Clinically significant laboratory or EKG abnormality or unstable medical condition
  • •For women of childbearing potential, unwillingness to use an acceptable form of contraception during the study
  • •Subjects needing concurrent use of psychotropic medications

Outcomes

Primary Outcomes

Response based on a criterion of 50% or greater reduction in the Marks Main Phobia Questionnaire and Marks Fear Questionnaire from baseline

Secondary Outcomes

  • Response based on CGI-I category

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 3
Escitalopram (Lexapro®) In Patients With Major Depression With Atypical FeaturesAtypical Depression
NCT00610506Duke University15
Completed
Phase 3
The Efficacy of Escitalopram for Negative Symptoms in SchizophreniaSchizophrenia
NCT00148447BeerYaakov Mental Health Center40
Completed
Phase 2
Escitalopram as a Mood Stabilizer for Bipolar II DisorderBipolar Disorders
NCT00156325The University of New South Wales10
Active, not recruiting
Not Applicable
Estudio clínico con Escitalopram para el tratamiento de la depresión, la ansiedad y el craving, asociados al alcoholismo. - Escitalopram en el tratamiento del alcoholismoTratamiento de la depresión, la ansiedad y el craving, asociados al alcoholismo.
EUCTR2005-006195-35-ESInstitut de Recerca / Hospital de Sant Pau
Completed
Phase 4
A Safety and Efficacy Study of Escitalopram on Acute Treatment of Severe DepressionMajor Depressive Disorder
NCT01814085Xian-Janssen Pharmaceutical Ltd.225